• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Spectranetics touts 100% survival rate in Bridge occlusion balloon study

Spectranetics touts 100% survival rate in Bridge occlusion balloon study

May 12, 2017 By Fink Densford

Spectranetics

Spectranetics (NSDQ:SPNC) today released data from a late breaking clinical trial of its Bridge occlusion balloon designed to reduce blood loss due to superior vena cava tears during lead extraction procedures, touting a 100% survival rate amongst patients treated with the balloon.

The company presented 1-year clinical experience data from the study today at the Heart Rhythm Society’s 38th Annual Scientific Sessions.

The Colorado Springs, Colo.-based company’s Bridge balloon is designed to reduce blood loss in the event of a tear and to provide a “bridge” to surgical intervention. The study aimed to explore the early impact of the balloon on the management of SVC tears as well as survival outcomes for patients treated.

“By having a tool that can occlude the bleeding and reduce exsanguination, you have a more stable patient. You also have more time to do a better repair, and therefore have a better outcome,” study investigator Dr. Roger Carrillo of the University of Miami Hospital told MassDevice.com in an interview.

In the study, researchers evaluated 35 confirmed SVC tears and 33 non-SVC events, with 9 confirmed SVC patients being treated with the Bridge balloon and 26 without. Of the 9 treated with the balloon, all patients were discharged alive from the hospital. Only 50% of patients with SVC events who were not treated with the balloon survived the procedure, according to the study.

“From a clinical point of view, [the Bridge balloon] makes a procedure that was safe, safer. Therefore, more patients can benefit from this procedure. Patients who were indicated that were afraid or concerned about the possibility of the risks are able to undergo the procedure with a higher degree of safety,” Dr. Carrillo said. “Tens of thousands of patients aren’t being referred for this procedure when indicated because of the risk. So by making the safe procedure safer, not only do we have more surviving patients, we have more patients who are willing to undergo the procedure.”

Researchers noted that SVC tears in the study occurred in populations identified as having a higher risk for complications, including female patients, patients with ICDs and those with leads 9.7 years or older.

Carrillo said that from a clinical perspective, the research reinforced the need to adjust workflows to plan for possible balloon use before the procedure.

“The important take away from the study is we need to change the workflow at the time of the extraction to make sure there is a guide wire and sheath before we proceed with the extraction,” Carrillo said. “That way we can use the potential benefits of the balloon.”

The company won FDA clearance for the Bridge balloon last February, indicated to temporarily occlude vessels during cardiac lead extraction procedures. After 1 year of clearance, approximately 40% of physicians are using the balloon during lead extraction procedures, Carrillo said, but he’d like to see the number grow.

“After 1 years, 40% of physicians do this, but I would like all of them to do that. I’d like to see it done in all patients. By changing the workflow, we can then be able to apply the balloon, because if it is not applied, once a complication occurs, you cannot float the balloon or position the balloon appropriately,” Carrillo said.

Filed Under: Cardiovascular, Catheters, Clinical Trials Tagged With: Spectranetics Corp.

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy